The Global Medtech Industry: Rewiring Medtech in a Post-Pandemic World
The medtech industry is undergoing rapid change to address evolving global market dynamics. This has been further accelerated by the pandemic. This white paper from IQVIA – an associate member of AdvaMed® – discusses how global markets and specific therapeutic areas are poised for growth over the next decade. Read this white paper to help inform business strategy.
Related Reading
Blog / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Why Lifesaving Medtech Should Be Tariff-free: An Interview with AdvaMed’s CEO
April 30, 2025
AdvaMed President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential, lifesaving medtech products.
News / China / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners
April 25, 2025
WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech.
Blog / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Why the Administration Should Be Flexible with Medtech Tariffs to Protect Patients and Innovation
April 25, 2025
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain
Tariffs: Understanding the Nairobi Protocol and related Customs Procedures
Now On Demand
Learn how the Nairobi Protocol may support duty-free access for medical devices under new tariffs. Join us April 30, 2–3:30pm ET.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Scott Whitaker Op-Ed: Tariffs Should Spare Vital U.S. MedTech Industry
April 17, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed® Advancements: Q1 2025 Report
April 15, 2025
AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.
News / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed Statement on President’s Reciprocal Tariff Pause
April 9, 2025
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
Resource / Coverage & Payment / Emerging Policy Response Resources / Global & Trade / Supply Chain / Tariffs
Amendment To Reciprocal Tariffs and Updated Duties as Applied to Low-Value Imports from The People’s Republic of China
April 9, 2025
Details a sweeping tariff hike to 84% on Chinese imports and de minimis increases, aiming to protect U.S. economic and national security.